RLMD vs FIP Comparison

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

FTAI Infrastructure Inc is engaged in five segments; Railroad segment, which includes eight freight railroads and one switching company that provide rail service to certain manufacturing and production facilities; the Jefferson Terminal segment, which consists of a multi-modal crude oil and refined products terminal and other related assets; The Repauno segment, which consists of a deep-water port located along the Delaware River with an underground storage cavern, a multipurpose dock, a rail-to-ship transloading system, and multiple industrial development opportunities; Power and Gas segment, which comprised Long Ridge, a multi-modal terminal located along the Ohio River; and Sustainability and Energy Transition segment, which comprised of Aleon/Gladieux, Clean Planet, and CarbonFree.